immutopics产品代理

产品分类 > 科研试剂 > immutopics产品代理

immutopics产品代理

Quidel Corporation(纳斯达克股票代码:QDEL)是一家总部位于加利福尼亚的领先诊断医疗保健制造商,致力于通过开发诊断解决方案来改善全球人民的健康和福祉,这些解决方案可以改善患者的治疗效果并为医疗保健提供经济效益系统。
Quidel 于 1979 年开始运营,并于 1983 年推出了第一批产品。此后,Quidel 通过内部开发和收购扩大了产品基础,重点是加大研发力度,以加快新产品的推出速度。我们的核心竞争力和能力包括免疫分析开发、自动化制造、单克隆抗体表征和开发以及分子分析开发。我们目前的产品大致分为以下几类: (1) 横向流动,我们是传染病和生殖健康领域的市场领导者; (2) 直接荧光抗体 (DFA),具有传染病和病毒学方面的专业知识; (3) 微量滴定生产,重点关注骨和补体通路市场; (4) 荧光免疫分析产品(Sofia); (5) 分子诊断产品,包括世界上第一个获得 FDA 批准的手持式分子设备 AmpliVue。作为强大产品管道的一部分,其他分子和索非亚测试目前正在开发或临床试验中。
无论是在我们位于加利福尼亚州圣地亚哥的总部,还是在我们位于俄亥俄州、马萨诸塞州或德国的研究和制造业务中,还是通过我们在世界各地的商业组织,Quidel 都提供来自先进横向流动和直接荧光的连续诊断解决方案分子诊断测试的抗体,可进一步提高医疗保健质量。
价格: 0.00

Quidel   Corporation (Nasdaq: QDEL) is a California-based leading diagnostic   healthcare manufacturer serving to enhance the health and well-being of   people around the globe through the development of diagnostic solutions that   can lead to improved patient outcomes and provide economic benefits to the   healthcare system.

   

Quidel commenced operations in 1979 and launched its first products in 1983. Since that time, Quidel has expanded its product base through internal development and acquisition with a focus on increasing its research and development efforts to accelerate the rate of new product introductions. 

Our core   competencies and capabilities include immunoassay development, automated   manufacturing, monoclonal antibody characterization and development, and   molecular assay development. Our current products fall generally into these   categories: (1) lateral flow, where we are market leaders in infectious   disease and reproductive health; (2) direct fluorescent antibodies (DFA),   with expertise in infectious disease and virology; (3) micro-titer   production, with a focus on bone and complement pathway markets; (4)   fluorescent immunoassay products (Sofia); and (5) molecular diagnostic   products including the world’s first FDA-cleared handheld molecular device, AmpliVue.   Additional molecular and Sofia tests are currently in development or in   clinical trials as part of a robust product pipeline.

   

Whether at our headquarters in San Diego, California, at our research and manufacturing operations in Ohio, Massachusetts, or in Germany, or through our Commercial organization around the world, Quidel is delivering a continuum of diagnostic solutions from advanced lateral-flow and direct fluorescent antibody to molecular diagnostic tests that further improve the quality of healthcare.